A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA (SkybriGHt)

Ascendis Pharma logo

Ascendis Pharma

Status

Enrolling

Conditions

Growth Hormone Deficiency

Treatments

Other: No intervention

Study type

Observational

Funder types

Industry

Identifiers

NCT05820672
ASND0037

Details and patient eligibility

About

The goal of this study is to genrate evidence on long-term effectiveness and safety of SKYTROFA (lonapegsomatropin) in patients with growth hormone deficiency under routine clinical care

Full description

Patients will be treated according to routine clinical practice, and no additional visits, examinations or tests will be required beyond those performed as part of routine clinical practice except for COAs.

Enrollment

900 estimated patients

Sex

All

Ages

1 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients who are on treatment with SKYTROFA (lonapegsomatropin)
  • Patients being clinically managed in USA
  • Patients with an appropriate written informed consent/assent as applicable for the age of the patient

Exclusion criteria

Patients participating in any interventional clinical study

Trial design

900 participants in 1 patient group

Patients on SKYTROFA Treatment
Description:
Patients on SKYTROFA Treatment managed in USA with appropriate written Informed Consent
Treatment:
Other: No intervention

Trial contacts and locations

0

Loading...

Central trial contact

Isabel Couto

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems